Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0007413
UniProt IDQ15369
Primary gene name(s)TCEB1
Synonym gene name(s)unknown
Protein nameTranscription elongation factor B polypeptide 1
Protein functionSIII, also known as elongin, is a general transcription elongation factor that increases the RNA polymerase II transcription elongation past template-encoded arresting sites. Subunit A is transcriptionally active and its transcription activity is strongly enhanced by binding to the dimeric complex of the SIII regulatory subunits B and C, elongin BC complex. {ECO:0000269|PubMed:15590694}.; FUNCTION: The elongin BC complex seems to be involved as an adapter protein in the proteasomal degradation of target proteins via different E3 ubiquitin ligase complexes, including the von Hippel-Lindau ubiquitination complex CBC(VHL. By binding to BC-box motifs it seems to link target recruitment subunits, like VHL and members of the SOCS box family, to Cullin/RBX1 modules that activate E2 ubiquitination enzymes. {ECO:0000269|PubMed:15590694}.
Subcellular locationNucleus {ECO:0000305}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: Q15369
Gene Ontology
(Biological Process)
Complete annatation
positive regulation of transcription elongation from RNA polymerase II promoter [GO:0032968];
protein ubiquitination involved in ubiquitin-dependent protein catabolic process [GO:0042787];
regulation of transcription from RNA polymerase II promoter [GO:0006357];
regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061418];
transcription elongation from RNA polymerase II promoter [GO:0006368];
transcription from RNA polymerase II promoter [GO:0006366];
viral process [GO:0016032]
Gene Ontology
(Molecular Function)
Complete annatation
Gene Ontology
(Cellular Component)
Complete annatation
cytosol [GO:0005829];
elongin complex [GO:0070449];
nucleoplasm [GO:0005654]
Protein-protein interaction112783
Phylogenetic treeQ15369
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD31.652799020740659.04527841738556e-077.08210058736806e-06
AZA vs. DISU0.03175261486903010.9005631673650830.993937521279788
AZA vs. IL70.3543075105679890.06793939502302950.742355521562595
AZA vs. SAHA-0.00848996884355150.972416375007810.992834220866143
DISU vs. CD3-1.633799456881391.12561686704815e-058.27281748117203e-05
DISU vs. IL70.3135445562701630.215261584945110.596470805094579
DISU vs. SAHA-0.0389425054423630.8940531077375830.973945010373438
DMSO vs. AZA-0.1488117930908430.3815574755172331
DMSO vs. CD3-1.811525541044964.11886668105765e-083.89656762539569e-07
DMSO vs. DISU-0.1821797977947030.4576070934077420.891520066361456
DMSO vs. IL70.5102190784445480.00503930672221720.145253439459702
DMSO vs. SAHA0.133065036213050.5750346427121680.852240751556348
HIV vs. Mock in Activation-0.227634635040210.7143817970718010.999983755607037
HIV vs. Mock in Latency-0.1514237182487040.3655488955719980.999834320637052
IL7 vs. CD3-1.290110158783277.96689613604684e-050.000477855254511079
SAHA vs. CD3-1.685931840554563.67264106582166e-062.59235132842775e-05
SAHA vs. IL7-0.3658860552220420.1352980951518850.344507345662079
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.283248 0.0381003
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.984 0.969 1.02 1.053 1.055
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

not found

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1LM8 X-ray 1.8Å C=17-112.
1LQB X-ray 2.0Å B=17-112.
1VCB X-ray 2.7Å B/E/H/K=1-112.
2C9W X-ray 1.9Å C=17-112.
2IZV X-ray 2.5Å C=17-112.
2MA9 NMR - C=19-109.
3DCG X-ray 2.4Å B/D=17-112.
3ZKJ X-ray 2.5Å B/E=17-112.
3ZNG X-ray 2.8Å B/E=17-112.
3ZRC X-ray 2.9Å B/E/H/K=17-112.
3ZRF X-ray 2.8Å B/E/H/K=17-112.
3ZTC X-ray 2.6Å B/E/H/K=17-112.
3ZTD X-ray 2.7Å B/E/H/K=17-112.
3ZUN X-ray 2.5Å B/E/H/K=17-112.
4AJY X-ray 1.7Å C=17-112.
4AWJ X-ray 2.5Å B/E/H/K=17-112.
4B95 X-ray 2.8Å B/E/H/K=18-112.
4B9K X-ray 2.0Å B/E/H/K=17-112.
4BKS X-ray 2.2Å B/E/H/K=17-112.
4BKT X-ray 2.3Å B/E/H/K=17-112.
4N9F X-ray 3.3Å 5/B/E/K/Q/T/Y/Z/h/n/t/z=17-112.
4W9C X-ray 2.2Å B/E/H/K=17-112.
4W9D X-ray 2.2Å B/E/H/K=17-112.
4W9E X-ray 2.6Å B/E/H/K=17-112.
4W9F X-ray 2.1Å B/E/H/K=17-112.
4W9G X-ray 2.7Å B/E/H/K=17-112.
4W9H X-ray 2.1Å B/E/H/K=17-112.
4W9I X-ray 2.4Å B/E/H/K=17-112.
4W9J X-ray 2.2Å B/E/H/K=17-112.
4W9K X-ray 2.1Å B/E/H/K=17-112.
4W9L X-ray 2.2Å B/E/H/K=17-112.
4WQO X-ray 3.2Å C=17-112.
5BO4 X-ray 2.9Å C/F/I/L/O/R=17-112.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa04066 HIF-1 signaling pathway - Homo sapiens (human)
hsa04120 Ubiquitin mediated proteolysis - Homo sapiens (human)
hsa05200 Pathways in cancer - Homo sapiens (human)
hsa05211 Renal cell carcinoma - Homo sapiens (human)